Spero Therapeutics to Provide Fourth Quarter and Full Year 2021 Business Update and Report… | national
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that it will host a conference call and live audio webcast on Thursday, March 31, 2022 at 4 p.m. a: 30 a.m. ET to announce its fourth quarter and full year 2021 financial results and provide an update on its business and pipeline.
To access the call, please dial 1-877-705-6003 (domestic) or 1-201-493-6725 (international) and refer to conference ID 13727002. The audio webcast can be viewed under ” Events and Presentations” in Investor and the Media section of the Company’s website at . The archived webcast will also be available on the Spero website for 30 days after the call.
About Spero Therapeutics Spero Therapeutics, Inc. is a clinical-stage, multi-asset biopharmaceutical company focused on the identification, development and commercialization of novel treatments for multidrug-resistant (MDR) bacterial infections and rare diseases.
Spero Therapeutics’ lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is in development as the first oral carbapenem antibiotic for use in cUIs, including pyelonephritis. On January 3, 2022, Spero Therapeutics announced that the FDA had accepted its NDA for tebipenem HBr tablets.
Tebipenem HBr is an investigational drug in the United States and is not currently approved for the treatment of complicated urinary tract infections, including pyelonephritis.
Spero Therapeutics is also developing SPR720 as a new oral therapy product candidate for the treatment of a rare orphan lung disease caused by non-tuberculous mycobacterial infections.
Spero Therapeutics also has a next-generation, intravenously administered polymyxin product candidate, SPR206, developed from its potentiation platform, which is being developed to treat multidrug-resistant Gram-negative infections in the hospital setting.
For more information, visit .
Investor Relations Contact: Ted Jenkins Vice President, Investor Relations and Specialty Finance [email protected] (617) 798-4039
Media Contact: Jacqueline Pomfret Kirby Vice President, Corporate Affairs [email protected] (617) 798-4074
Copyright 2022 GlobeNewswire, Inc.